Moustafa Eldick, MD
Internal Medicine · Crescent City, FLNPI 1962592907
Payments from drug & device makers
Across 352 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$775
- Sunovion Pharmaceuticals Inc.$574
- Boehringer Ingelheim$348
- AstraZeneca$278
- Lilly USA, LLC$180
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,373100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 106 | $1,461 |
| AbbVie(2 entities) | 63 | $775 |
| Sunovion Pharmaceuticals Inc. | 31 | $574 |
| Boehringer Ingelheim | 23 | $348 |
| AstraZeneca | 19 | $278 |
| Lilly USA, LLC | 13 | $180 |
| Medtronic | 12 | $179 |
| Bayer | 9 | $178 |
| Novo Nordisk | 10 | $175 |
| Pfizer | 11 | $173 |
| Teva Pharmaceuticals USA, Inc. | 6 | $123 |
| Sumitomo Pharma America, Inc. | 7 | $116 |
| Novartis | 5 | $81 |
| Mylan Specialty L.p. | 3 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Vertex | 2 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Johnson & Johnson | 3 | $56 |
| Catalyst Pharmaceuticals, Inc. | 2 | $52 |
| Exact Sciences | 3 | $47 |
| Inogen, Inc. | 2 | $37 |
| Evoke Pharma, Inc. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $24 |
| Alk-abello, Inc | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$5,373 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 211 | $275,135 |
| EliquisApixaban | 308 | $211,165 |
| Cosentyx Sensoready PenSecukinumab | 11 | $162,846 |
| OzempicSemaglutide | 118 | $158,105 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 174 | $143,797 |
| MounjaroTirzepatide | 90 | $123,939 |
| VraylarCariprazine Hcl | 74 | $114,249 |
| UbrelvyUbrogepant | 25 | $75,629 |
| XifaxanRifaximin | 22 | $75,574 |
| JardianceEmpagliflozin | 58 | $69,306 |
| AptiomEslicarbazepine Acetate | 67 | $67,833 |
| LofenaDiclofenac Potassium | 15 | $64,202 |
| FarxigaDapagliflozin Propanediol | 63 | $54,652 |
| LinzessLinaclotide | 53 | $53,158 |
| NuplazidPimavanserin Tartrate | 12 | $41,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $180 | $399,074301 claims |
| AbbVieVraylar, Ubrelvy, Linzess, Restasis | $775 | $255,477165 claims |
| PfizerEliquis | $173 | $211,165308 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,461 | $195,613246 claims |
| Novo NordiskOzempic | $175 | $158,105118 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Synjardy Xr, Tradjenta, Stiolto Respimat | $348 | $131,058161 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $278 | $106,948188 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $65 | $75,57422 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $574 | $67,83367 claims |
| NovartisEntresto | $81 | $38,50346 claims |
| Johnson & JohnsonXarelto | $56 | $31,37872 claims |
| MerckJanuvia | $19 | $22,93818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Crescent City
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.